Keyphrases
Small Molecule Inhibitors
100%
Knockdown
100%
Epigenetic Modulators
100%
PROTAC Degraders
100%
Drug Discovery
50%
High-order
50%
In Cancer
50%
Cancer Treatment
50%
Gene Expression
50%
Cancer Types
50%
Vulnerability
50%
Specificity Protein 1
50%
Drug Target
50%
Drug Resistance
50%
Dysregulation
50%
Disease Pathogenesis
50%
Epigenetics
50%
Phenotypic Effects
50%
Therapeutic Approaches
50%
Post-translational
50%
Epigenetic Mechanisms
50%
Synthetic Lethality
50%
Target Druggability
50%
Hematological Malignancies
50%
Targeted Drugs
50%
External Stimuli
50%
CRISPR Interference (CRISPRi)
50%
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
50%
FDA-approved Drugs
50%
Epigenetic Drugs
50%
Proteolysis Targeting chimera (PROTAC)
50%
Degrader
50%
Targeted Protein Degradation
50%
Epigenetic Diseases
50%
Genome-wide RNAi Screen
50%
Epigenetic Targeting
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Drug Discovery
50%
Drug Delivery System
50%
Drug Resistance
50%
Lethality
50%
Hematologic Malignancy
50%
Diseases
50%
Immunology and Microbiology
Clustered Regularly Interspaced Short Palindromic Repeat
100%
Gene Expression
50%
Protein Degradation
50%
RNA Interference
50%
Drug Resistance
50%
Drug Targeting
50%
Chemistry
Proteolysis Targeting Chimera
100%
Drug Target
33%
Drug Discovery
33%
Haematological
33%
Protein Degradation
33%
Gene Expression
33%
RNA Interference
33%
Biochemistry, Genetics and Molecular Biology
Epigenetics
100%
Small Molecule
33%
CRISPR
33%
Gene Expression
16%
Genetics
16%
Protein Catabolism
16%
RNA Interference
16%
Drug Resistance
16%
Drug Targeting
16%